- Premium Content It takes our newsroom weeks - if not months - to investigate and produce stories for our premium content. You can’t find them anywhere else.
A Singapore startup has a real shot at stamping out cancer deaths
It was an unusual sight: over 200 seniors gathered in a typically quiet community center in Singapore on a Saturday – not for a line dancing routine, but to have their blood drawn.
Adding to the pomp was a special guest: Singapore Prime Minister Lee Hsien Loong. As he shook hands and made small talk, he flashed a grin.
The seniors, sponsored by charities, were undergoing a cutting-edge early detection test for stomach cancer. The Singaporean biotech startup Mirxes (pronounced Mer-raxis) was behind the test.

Singapore Prime Minister Lee Hsien Loong making the rounds / Photo credit: Clement from MCI
The company is chasing after the holy grail of medicine: the prevention of cancer. The ticking bomb causes one in six deaths worldwide, and could prove more lethal in an aging population.
Cancer is an insidious killer because its symptoms often don’t manifest until much later. Stomach (or gastric) cancer is a good example: it’s not the most prevalent, but it’s one of the hardest to spot. That’s partly because endoscopy, the method typically used to detect it, involves passing a thin tube with an attached camera down the throat and into the gut – an invasive, manual process.
The value of smarter detection
Mirxes’ test, called GastroClear, is less daunting. After a patient’s blood is drawn, the sample is sent to a lab and analyzed for markers that indicate the likelihood of stomach cancer.
Patients receive a simple, color-coded score, allowing doctors to formulate action plans. It’s a sort of early warning system: green means there’s nothing to worry about, yellow means the person has an above-average likelihood of getting cancer, and red means the person is at risk.
“Instead of just trying to save the one person who has late-stage cancer, we’re trying to save the nine people that don’t have cancer,” Isaac Ho, chief investment officer of Mirxes, tells Tech in Asia.
The test results give people a chance to change cancer-causing lifestyle habits before it’s too late. For those genetically predisposed to the disease, it’s a reminder that they should constantly get checked to increase the odds of early detection and survival.
Cancer prevention benefits not just individuals at risk, but the bigger picture too. Prevention means less congestion in hospitals. It also reduces the burden on caregivers, as well as family and friends: those who bear the financial and emotional costs of caring for loved ones.

Gastric cancer test kit / Photo credit: Mirxes
Mirxes’ potential has attracted high-profile investors.
Science flex
Breakout market
Long to-do list
Human quirks
Stay ahead in Asia’s tech landscape
This is premium content. Subscribe to read the full story.
Mirxes claims to be the first early cancer detection company of any kind to commercialize.
We know this is not ideal. ⌛ Sign up in 20 seconds. Cancel anytime.
Our subscriber community includes professionals from these companies:





Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
